Exploratory study on the cardiovascular system of DPP-4 inhibitors in angina patients underwent PCI after complicated with type 2 diabetes
- Conditions
- Type 2 diabetic patients with angina pectoris who undergo percutaneous coronary intervention
- Registration Number
- JPRN-UMIN000011145
- Lead Sponsor
- Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1) Type 1 diabetes mellitus 2) Severe diabetic ketosis, diabetic coma or total coma within 6 months 3) Patients who have 90% or more of the stenosis without PCI culprit lesion 4) Undergoing hemodialysis 5) Severe infectious disease ,before or after surgery, and sever trauma 6) Occurrence of ischemic stroke, hemorrhagic stroke or TIA within 6 months 7) Moderate or severe heart failure (NYHA III or IV) 8) Patients who did not receive DPP4 inhibitors during 3 month before starting study 9) Under treatment with insulin 10) Pregnant,lactating, possibly pregnant or planning to become pregnant women 11) Past medical history of hypersensitivity to linagliptin 12) Patients considered as inadequate by the principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) The change of HbA1 at baseline and 8months after DPP-4 inhibitor treatment. 2) The change of plaque volume of non-culprit lesion at 8 months after PCI. 3) The change of virtual histology of non-culprit lesion segment at 8 months after PCI. 4) The co-relationship between HbA1c redaction and the change of plaque volume
- Secondary Outcome Measures
Name Time Method 1) Plasma glucose 2) Serum lipids 3) Peripheral blood CD-34 positive cells 4) High sensitive CRP 5) BNP 6) Blood pressure 7) Body weight 8) Safety